Brukinsa Evrópusambandið - íslenska - EMA (European Medicines Agency)

brukinsa

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - Æxlishemjandi lyf - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Requip Depot Forðatafla 2 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

requip depot forðatafla 2 mg

glaxosmithkline pharma a/s - ropinirolum hýdróklóríð - forðatafla - 2 mg

Requip Depot Forðatafla 4 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

requip depot forðatafla 4 mg

glaxosmithkline pharma a/s - ropinirolum hýdróklóríð - forðatafla - 4 mg

Requip Depot Forðatafla 8 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

requip depot forðatafla 8 mg

glaxosmithkline pharma a/s - ropinirolum hýdróklóríð - forðatafla - 8 mg

Erlotinib WH Filmuhúðuð tafla 100 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

erlotinib wh filmuhúðuð tafla 100 mg

williams & halls ehf. - erlotinibum hýdróklóríð - filmuhúðuð tafla - 100 mg

Erlotinib WH Filmuhúðuð tafla 150 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

erlotinib wh filmuhúðuð tafla 150 mg

williams & halls ehf. - erlotinibum hýdróklóríð - filmuhúðuð tafla - 150 mg